Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia, Myelodysplastic Syndromes
Interventions: vosaroxin; Drug
Lead sponsor: Sunesis Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 13 more

Conditions: Obesity
Interventions: Meal challenge; Other
Lead sponsor: North Dakota State University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Geographic Atrophy, Age-Related Macular Degeneration, AMD
Interventions: OT-551 antioxidant eye drop; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 60 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Down Syndrome
Interventions: Placebo, RO5186582; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more

Conditions: Ankle Fractures
Interventions: Postoperative protocol (Immediate weight bearing), Postoperative Protocol (Delayed Weight Bearing); Other
Lead sponsor: Kyle Schweser MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy
Interventions: Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hepatobiliary Diseases
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Interventions: Subcutaneous Blinatumomab; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions: Aflibercept; Drug
Lead sponsor: Tennessee Retina; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Lexington, Kentucky • Nashville, Tennessee

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Year to 74 Years · Male only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 4
States / cities: Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Hypertension, Systolic, Stiffness, Aortic
Interventions: Clonidine, Hydrochlorothiazide, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Cervical Cancer
Interventions: Lay Health Advisor Education Intervention, Usual Care Group; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Carcinoma, Renal Cell
Interventions: DFF332, RAD001, PDR001, NIR178; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more

Conditions: ADHD
Interventions: OROS-Methylphenidate (MPH); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Years to 11 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Cincinnati, Ohio • Seattle, Washington

Conditions: Total Knee Arthroplasty, Knee Replacement, Knee Replacement Arthroplasty, Knee Osteoarthritis
Interventions: Smart Knee Implant; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Medulloblastoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years to 30 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node
Interventions: Sample Collection; Other
Lead sponsor: Castleman Disease Collaborative Network; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation, Stroke
Interventions: Chart Review; Other
Lead sponsor: MaineHealth; Other
Eligibility: Not listed
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockport, Maine

Conditions: Influenza
Interventions: DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: End Stage Renal Disease
Interventions: there is no intervention; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 21 Years
Enrollment: 150 participants
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Venous Thromboembolism
Interventions: fondaparinux sodium, sequential compression devices; Drug · Device
Lead sponsor: Mary Knudson, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis
Interventions: Dupilumab SAR231893; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Interventions: Faricimab, OLN324; Drug
Lead sponsor: Ollin Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 29
States / cities: Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more

Conditions: Hypertension, Dyslipidemias
Interventions: DASH diet counseling; Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: West Lafayette, Indiana

Search by objective public record fields.

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Gut Microbiota Post Roux-en-Y Gastric Bypass Surgery

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Immediate Vs. Delayed Weight Bearing Postoperative Protocol in Diabetic Ankle Fractures

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Sympathetic Regulation of Large Artery Stiffness in Humans With ISH

Community Awareness Resources and Education - Project 1

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

The Effects of ADHD Medication (TEAM) Study

Investigating Patient Satisfaction With Smart Knee Implants

Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma

Castleman Disease Collaborative Network Biobank

Echocardiographic Risk Factors of Stroke in Patients With Atrial Fibrillation

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults